Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Date:8/5/2009

the following: There can be no assurance that the Company will complete cost-effective clinical trials or meet the projected development timelines for the drug candidates in its pipeline, including Zerenex and KRX-0401; that the Company will be able to raise additional capital in the future in order to fund its operations; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available athttp://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    KERYX CONTACT:
    Lauren Fischer
    Director - Investor Relations
    Keryx Biopharmaceuticals, Inc.
    Tel: 212.531.5965
    E-mail: lfischer@keryx.com

                              Keryx Biopharmaceuticals, Inc.
                           Selected Consolidated Financial Data
                    (In Thousands, Except Share and Per Share Amounts)

    Statements of Operations Information:

                                   Three Months Ended     Six Months Ended
                                        June 30,               June 30,
                                      (unaudited)            (unaudited)
                                    2009       2008        2009       2008


    REVENUE:
    License revenue            $  18,289     $  327   $  21,616     $  526
    Service revenue                   --         62           3         62
    Other reven
'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015 According ... (DNA, RNA, XNA), by Application (Diagnostics, Therapeutics, R&D), by Technology ... & Pharmaceutical Companies, CRO) - Global Forecast to 2020", published ... $244.93 Million by 2020 from $107.56 Million in 2015, at ... T ables and 67 F igures ...
(Date:6/29/2015)... --  For the seventh year running, Across Health conducted a ... maturity called the Multichannel Maturometer . The research ... fast enough. While it,s true that technology is indeed ... customers are increasingly "digital natives", pharma still lags behind ... Logo ...
(Date:6/26/2015)... , June 26, 2015   Aratana ... a pet therapeutics company focused on the ... products for companion animals, today announced positive ... of capromorelin (AT-002), the company,s innovative therapeutic ... a small molecule that mimics ghrelin, the ...
(Date:6/26/2015)... Va. , June 26, 2015  A San ... two products made with synthetic rhino horn: beer in ... Vietnam . In response to the ... the manufacture, marketing and sale of synthetic rhino horn.  ... and Save the Rhino International (SRI) ...
Breaking Biology Technology:Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5Rhino Experts Oppose Synthetic Rhino Horn as Solution to Poaching Crisis 2
... FOLD ) today announced that John Crowley, President and ... Merrill Lynch,Global Pharmaceutical, Biotech & Medtech 2007 Conference in ... BDT (11:00 am EDT) at the,Merrill Lynch Financial Centre. ... will be available to all,interested parties through the Investors ...
... a,biotechnology company translating the complexity of human biology ... president and,CEO, Dr. Keith O. Elliston, has been ... in Arlington, Va., September 17-18. Dr. Elliston ... Development and Commercial Value Added in Care Delivery ...
... ... and Reusable Bottles, MONROVIA, Calif., Sept. 12 Bottled or ... of consumers who fear the impact of,bottled water on the environment, ... assembled a family of products on its website, http://www.discovertesting.com, in ...
Cached Biology Technology:Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference 2Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference 3Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit 2Discover Testing Settles the Drinking Water Debate: Tap vs. Bottled 2
(Date:6/23/2015)... June 22, 2015 ... addition of the "Body-Worn Temperature Sensors Market ... and Forecast 2014 - 2020" report to ... analysis of the global body-worn temperature sensors market. ... segmented on the basis of types, care setting, ...
(Date:6/18/2015)... Conn. , June 18, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market announces ... a featured segment on "Money on the Mark", scheduled to ... City June 20 th . ... will be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a leading ... that its U.are.U ® 4500 fingerprint readers ... Eateries, Inc., a San Jose, ... to increase security, improve accountability and reduce fraud ... instant, non-repudiable identity confirmation for employee sign in ...
Breaking Biology News(10 mins):Body-Worn Temperature Sensors Market - Global Industry Analysis 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... today announced that it will launch EMBO Press on ... for The EMBO Journal , EMBO reports , ... provides opportunities for the future development of the journals. ... to encourage transparency in the publication process and help researchers make ...
... is derived from brain tumor stem cells, the source ... unclear. The potential of neural stem cells to transform ... but has not been confirmed. A team led by ... Nanjing Medical University, China found that doxycycline-induced neural stem ...
... Queen,s University Belfast is a lead partner in a ... new ways to treat Cystic Fibrosis. Affecting more ... is one of the most common life-threatening inherited diseases. ... death for patients., The new global programme, known as ...
Cached Biology News:EMBO announces the launch of EMBO Press 2Queen's University in €6m bid to find new Cystic Fibrosis treatments 2Queen's University in €6m bid to find new Cystic Fibrosis treatments 3
... consumable measurement plate for QPatch. ... controlled measurement sites. Each measurement ... flow channel system that enables ... and compound applications necessary for ...
This bispecific antibody complex has been tested for efficient depletion of CD41+ cells using the StemSep ; negative immunomagnetic cell separation system....
... to supply microplates, deepwells, and tips to ... in mind, iLink incorporates multiple functions into ... iLink software is the key to building ... can be copied and installed as turnkey ...
No-Weigh Dithiothreitol (DTT) ,7.7 mg DTT/Tube x 48 tubes...
Biology Products: